Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Link opens in a new tab
English
Español
Search content at University of Kentucky
Home
Research units
Researchers
Projects & Grants
Research Output
Facilities & Equipment
Honors & Awards
Activities
Unexpected mortality reduction with abciximab for in-stent restenosis
Debabrata Mukherjee
, Joel P. Reginelli
,
David J. Moliterno
, Jay S. Yadav
, Jakob P. Schneider
, Russell Raymond
, Patrick L. Whitlow
, Irving Franco
, Eric J. Topol
, Stephen G. Ellis
Internal Medicine
Cardiovascular Research Priority Area
Research output
:
Contribution to journal
›
Article
›
peer-review
9
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Unexpected mortality reduction with abciximab for in-stent restenosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
In-Stent Restenosis
100%
Abciximab
100%
Percutaneous Coronary Intervention
37%
Myocardial Infarction
25%
Diabetes Mellitus
12%
Prospective Study
12%
Hypercholesterolemia
12%
Brachytherapy
12%
Patient History of Coronary Artery Bypass Graft
12%
Revascularization
12%
Heart Left Ventricle Function
12%
Directional Atherectomy
12%
Low Level Laser Therapy
12%
Low Risk Population
12%
Nursing and Health Professions
ReoPro
100%
In-Stent Restenosis
100%
Percutaneous Coronary Intervention
37%
Heart Infarction
25%
Patient History of Coronary Artery Bypass Graft
12%
Directional Atherectomy
12%
Low Level Laser Therapy
12%
Low Risk Population
12%
Hypercholesterolemia
12%
Revascularization
12%
Diabetes Mellitus
12%
Brachytherapy
12%
Pharmacology, Toxicology and Pharmaceutical Science
In-Stent Restenosis
100%
Abciximab
100%
Heart Infarction
25%
Prospective Study
12%
Patient History of Coronary Artery Bypass Graft
12%
Diabetes Mellitus
12%
Hypercholesterolemia
12%
Immunology and Microbiology
Abciximab
100%
Coronary Artery
12%
Artery Bypass
12%
Heart Left Ventricle Function
12%
Low Risk Population
12%
Revascularization
12%
Neuroscience
Abciximab
100%
Myocardial Infarction
25%
Diabetes Mellitus
12%